Blueprint Medicines Reports First Quarter 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Blueprint Medicines (BPMC) Tops Q1 EPS by 11c
May 3, 2022 7:05 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.79), $0.11 better than the analyst estimate of ($1.90). Revenue for the quarter came in at $62.73 million versus the consensus estimate of $38.96 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More